Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker CYTK
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | B Lynne Parshall Director | CYTK Cytokinetics, Incorporated | 5,000 | $268.4K | 10b5-1 | Nov 9, 2026 | Form 4 ↗ 3 days later · 5,000 shares | Form 144 ↗ |
| Oct 20, 2026 | Fady Malik Officer | CYTK Cytokinetics, Incorporated | 16,386 | $1.0M | 10b5-1 | Oct 20, 2026 | Form 4 ↗ same day · 3,500 shares | Form 144 ↗ |
| Oct 13, 2026 | Robert Blum Director, Officer | CYTK Cytokinetics, Incorporated | 22,500 | $1.4M | 10b5-1 | Oct 12, 2026 | Form 4 ↗ 20 days later · 7,500 shares | Form 144 ↗ |
| Sep 15, 2026 | Robert I. Blum President, CEO, Director | CYTK Cytokinetics, Incorporated | 97,926 | $7.1M | — | Sep 15, 2026 | Form 4 ↗ same day · 105,426 shares | Form 144 ↗ |
| Sep 11, 2026 | Robert Landry Director | CYTK Cytokinetics, Incorporated | 2,000 | $147.2K | 10b5-1 | Sep 11, 2026 | Form 4 ↗ same day · 1,000 shares | Form 144 ↗ |
| Sep 1, 2026 | B Lynne Parshall Director | CYTK Cytokinetics, Incorporated | 5,000 | $354.6K | 10b5-1 | Sep 1, 2026 | Form 4 ↗ same day · 5,000 shares | Form 144 ↗ |
| Jul 30, 2026 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 24,000 | $1.9M | 10b5-1 | Jul 30, 2026 | Form 4 ↗ same day · 14,000 shares | Form 144 ↗ |
| Jul 7, 2026 | Fady Malik Officer | CYTK Cytokinetics, Incorporated | 24,500 | $2.1M | 10b5-1 | Jul 7, 2026 | Form 4 ↗ same day · 3,500 shares | Form 144 ↗ |
| Jul 1, 2026 | Robert Blum Director, Officer | CYTK Cytokinetics, Incorporated | 52,500 | $4.5M | 10b5-1 | Jul 1, 2026 | Form 4 ↗ 1 day later · 7,500 shares | Form 144 ↗ |
| Jun 29, 2026 | Sung Lee Officer | CYTK Cytokinetics, Incorporated | 9,503 | $781.1K | 10b5-1 | Jun 29, 2026 | Form 4 ↗ same day · 3,134 shares | Form 144 ↗ |
| Jun 26, 2026 | Sung Lee Officer | CYTK Cytokinetics, Incorporated | 6,695 | $541.0K | 10b5-1 | Jun 26, 2026 | Form 4 ↗ 3 days later · 3,134 shares | Form 144 ↗ |
| Jun 24, 2026 | Sung Lee Officer | CYTK Cytokinetics, Incorporated | 38,730 | $3.1M | 10b5-1 | Jun 24, 2026 | Form 4 ↗ 5 days later · 38,730 shares | Form 144 ↗ |
| Jun 1, 2026 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 2,933 | $225.1K | 10b5-1 | Jun 1, 2026 | Form 4 ↗ same day · 2,933 shares | Form 144 ↗ |
| May 5, 2026 | Wendell Wierenga Director | CYTK Cytokinetics, Incorporated | 4,032 | $266.3K | 10b5-1 | May 5, 2026 | Form 4 ↗ same day · 4,032 shares | Form 144 ↗ |
| May 5, 2026 | John Henderson Director | CYTK Cytokinetics, Incorporated | 20,000 | $1.3M | 10b5-1 | May 5, 2026 | Form 4 ↗ same day · 20,000 shares | Form 144 ↗ |
| May 5, 2026 | Sung Lee Officer | CYTK Cytokinetics, Incorporated | 23,906 | $1.6M | 10b5-1 | May 5, 2026 | Form 4 ↗ same day · 23,906 shares | Form 144 ↗ |
| Apr 15, 2026 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 79,639 | $5.3M | 10b5-1 | Apr 15, 2026 | Form 4 ↗ same day · 7,449 shares | Form 144 ↗ |
| Apr 7, 2026 | Fady Malik Officer | CYTK Cytokinetics, Incorporated | 22,000 | $1.4M | 10b5-1 | Apr 7, 2026 | Form 4 ↗ 1 day later · 4,500 shares | Form 144 ↗ |
| Apr 1, 2026 | Robert Blum Director, Officer | CYTK Cytokinetics, Incorporated | 45,000 | $3.0M | 10b5-1 | Apr 1, 2026 | Form 4 ↗ same day · 7,500 shares | Form 144 ↗ |
| Mar 31, 2026 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 3,639 | $229.1K | 10b5-1 | Mar 31, 2026 | Form 4 ↗ same day · 3,639 shares | Form 144 ↗ |
| Mar 18, 2026 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 1,930 | $119.9K | 10b5-1 | Mar 18, 2026 | Form 4 ↗ same day · 1,930 shares | Form 144 ↗ |
| Mar 16, 2026 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 1,709 | $102.6K | 10b5-1 | Mar 16, 2026 | Form 4 ↗ same day · 1,709 shares | Form 144 ↗ |
| Mar 2, 2026 | B Lynne Parshall Director | CYTK Cytokinetics, Incorporated | 10,000 | $622.2K | 10b5-1 | Mar 2, 2026 | Form 4 ↗ same day · 5,000 shares | Form 144 ↗ |
| Jan 2, 2026 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 59,570 | $3.8M | 10b5-1 | Jan 2, 2026 | Form 4 ↗ same day · 1,798 shares | Form 144 ↗ |
| Dec 29, 2025 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 1,809 | $114.2K | 10b5-1 | Dec 29, 2025 | Form 4 ↗ 1 day later · 1,809 shares | Form 144 ↗ |
| Dec 22, 2025 | Wendell Wierenga Director | CYTK Cytokinetics, Incorporated | 20,000 | $1.3M | 10b5-1 | Dec 22, 2025 | Form 4 ↗ 1 day later · 20,000 shares | Form 144 ↗ |
| Dec 5, 2025 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 53,528 | $3.6M | 10b5-1 | Dec 5, 2025 | Form 4 ↗ same day · 52,486 shares | Form 144 ↗ |
| Dec 2, 2025 | John T Henderson Director | CYTK Cytokinetics, Incorporated | 8,750 | $577.9K | 10b5-1 | Dec 2, 2025 | Form 4 ↗ same day · 8,750 shares | Form 144 ↗ |
| Dec 1, 2025 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 28,064 | $1.9M | 10b5-1 | Dec 1, 2025 | Form 4 ↗ 1 day later · 28,064 shares | Form 144 ↗ |
| Nov 19, 2025 | B Lynne Parshall Director | CYTK Cytokinetics, Incorporated | 5,000 | $330.8K | 10b5-1 | Nov 19, 2025 | Form 4 ↗ same day · 5,000 shares | Form 144 ↗ |
| Nov 12, 2025 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 5,175 | $321.9K | 10b5-1 | Nov 11, 2025 | Form 4 ↗ 20 days later · 28,064 shares | Form 144 ↗ |
| Oct 27, 2025 | Wendell Wierenga Director | CYTK Cytokinetics, Incorporated | 4,375 | $253.0K | 10b5-1 | Oct 27, 2025 | Form 4 ↗ same day · 4,375 shares | Form 144 ↗ |
| Oct 21, 2025 | Fady Malik Officer | CYTK Cytokinetics, Incorporated | 11,000 | $652.9K | 10b5-1 | Oct 21, 2025 | Form 4 ↗ same day · 2,105 shares | Form 144 ↗ |
| Oct 6, 2025 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 6,757 | $384.9K | 10b5-1 | Oct 6, 2025 | Form 4 ↗ same day · 6,757 shares | Form 144 ↗ |
| Oct 1, 2025 | Robert Blum Director, Officer | CYTK Cytokinetics, Incorporated | 15,000 | $824.4K | 10b5-1 | Oct 1, 2025 | Form 4 ↗ same day · 5,000 shares | Form 144 ↗ |
| Sep 30, 2025 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 6,695 | $360.8K | 10b5-1 | Sep 30, 2025 | Form 4 ↗ same day · 6,695 shares | Form 144 ↗ |
| Sep 2, 2025 | Robert Harrington Director | CYTK Cytokinetics, Incorporated | 4,300 | $151.9K | 10b5-1 | Sep 2, 2025 | Form 4 ↗ same day · 2,150 shares | Form 144 ↗ |
| Sep 2, 2025 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 6,756 | $238.7K | 10b5-1 | Sep 2, 2025 | Form 4 ↗ same day · 6,756 shares | Form 144 ↗ |
| Jul 8, 2025 | Fady Malik Officer | CYTK Cytokinetics, Incorporated | 14,000 | $467.0K | 10b5-1 | Jul 8, 2025 | Form 4 ↗ same day · 2,000 shares | Form 144 ↗ |
| Jun 16, 2025 | Robert Blum Director, Officer | CYTK Cytokinetics, Incorporated | 35,000 | $1.2M | 10b5-1 | Jun 16, 2025 | Form 4 ↗ same day · 5,000 shares | Form 144 ↗ |
| Jun 5, 2025 | Edward Kaye Director | CYTK Cytokinetics, Incorporated | 3,636 | $117.8K | 10b5-1 | Jun 5, 2025 | Form 4 ↗ same day · 3,636 shares | Form 144 ↗ |
| May 15, 2025 | Muna Bhanji Director | CYTK Cytokinetics, Incorporated | 1,454 | $43.6K | 10b5-1 | May 15, 2025 | Form 4 ↗ same day · 1,454 shares | Form 144 ↗ |
| Apr 21, 2025 | Wendell Wierenga Director | CYTK Cytokinetics, Incorporated | 20,000 | $769.1K | 10b5-1 | Apr 21, 2025 | Form 4 ↗ same day · 20,000 shares | Form 144 ↗ |
| Apr 15, 2025 | John T. Henderson Director | CYTK Cytokinetics, Incorporated | 3,190 | $127.0K | 10b5-1 | Apr 15, 2025 | Form 4 ↗ 1 day later · 3,190 shares | Form 144 ↗ |
| Apr 8, 2025 | Fady Malik Officer | CYTK Cytokinetics, Incorporated | 12,000 | $431.9K | 10b5-1 | Apr 8, 2025 | Form 4 ↗ same day · 2,000 shares | Form 144 ↗ |
| Apr 7, 2025 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 15,547 | $580.8K | 10b5-1 | Apr 7, 2025 | Form 4 ↗ same day · 2,886 shares | Form 144 ↗ |
| Mar 14, 2025 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 21,000 | $932.4K | 10b5-1 | Mar 14, 2025 | Form 4 ↗ same day · 100 shares | Form 144 ↗ |
| Mar 13, 2025 | Andrew Callos Officer | CYTK Cytokinetics, Incorporated | 26,771 | $1.2M | 10b5-1 | Mar 13, 2025 | Form 4 ↗ same day · 26,771 shares | Form 144 ↗ |
| Mar 5, 2025 | Robert Blum Director, Officer | CYTK Cytokinetics, Incorporated | 85,000 | $3.7M | 10b5-1 | Mar 5, 2025 | Form 4 ↗ same day · 25,000 shares | Form 144 ↗ |
| Mar 4, 2025 | Robert Harrington Director | CYTK Cytokinetics, Incorporated | 1,350 | $57.9K | 10b5-1 | Mar 4, 2025 | Form 4 ↗ same day · 900 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 8:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances